{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:01:45Z","timestamp":1791262905672,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"DOI":"10.1097\/qai.0b013e31827a2a7a","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T09:06:59Z","timestamp":1354180019000},"page":"381-387","source":"Crossref","is-referenced-by-count":40,"title":["Risk of Virological Failure and Drug Resistance During First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal"],"prefix":"10.1097","volume":"62","author":[{"given":"Pierre","family":"De Beaudrap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa","family":"Thiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assane","family":"Diouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coumba","family":"Toure-Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nd\u00e8ye F.","family":"Ngom-Gu\u00e8ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souleymane","family":"Mboup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Ndoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papa S.","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-3-20210131","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00002030-200207050-00008","article-title":". The Senegalese governments highly active antiretroviral therapy initiative: an 18-month follow-up study.","volume":"16","author":"Laurent","year":"2002","journal-title":"AIDS"},{"key":"R3-3-20210131","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0140-6736(02)09330-3","article-title":". Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients response, survival, and drug resistance.","volume":"360","author":"Weidle","year":"2002","journal-title":"Lancet"},{"key":"R4-3-20210131","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/135965350300800505","article-title":". Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote dIvoire.","volume":"8","author":"Seyler","year":"2003","journal-title":"Antivir Ther"},{"key":"R6-3-20210131","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/01.aids.0000226959.87471.01","article-title":". Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.","volume":"20","author":"Etard","year":"2006","journal-title":"AIDS"},{"key":"R7-3-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","article-title":". Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.","volume":"367","author":"Braitstein","year":"2006","journal-title":"Lancet"},{"key":"R8-3-20210131","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/QAD.0b013e328349822f","article-title":". Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.","volume":"25","author":"Keiser","year":"2011","journal-title":"AIDS"},{"key":"R9-3-20210131","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/QAD.0b013e32832e05b2","article-title":". Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.","volume":"23","author":"Keiser","year":"2009","journal-title":"AIDS"},{"key":"R10-3-20210131","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/QAD.0b013e32832ac34e","article-title":". The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.","volume":"23","author":"Hosseinipour","year":"2009","journal-title":"AIDS"},{"key":"R12-3-20210131","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/00002030-200305020-00010","article-title":". Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal.","volume":"17","author":"Landman","year":"2003","journal-title":"AIDS"},{"key":"R13-3-20210131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/1545109709344352","article-title":". Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients.","volume":"8","author":"Landman","year":"2009","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"R14-3-20210131","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/01.aids.0000162337.58557.3d","article-title":". Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.","volume":"19","author":"Phillips","year":"2005","journal-title":"AIDS"},{"key":"R15-3-20210131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/aid.2010.0201","article-title":". High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, Democratic Republic of the Congo.","volume":"27","author":"Djoko","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R17-3-20210131","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/aje\/kwr141","article-title":". Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in North America.","volume":"174","author":"Abraham","year":"2011","journal-title":"Am J Epidemiol"},{"key":"R19-3-20210131","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.2517-6161.1976.tb01597.x","article-title":"The empirical distribution function with arbitrarily grouped, censored and truncated data.","volume":"38","author":"Turnbull","year":"1976","journal-title":"J R Stat Soc"},{"key":"R21-3-20210131","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/(SICI)1097-0258(19961030)15:20<2177::AID-SIM345>3.0.CO;2-7","article-title":"Regression models for interval censored survival data: application to HIV infection in Danish homosexual men.","volume":"15","author":"Carstensen","year":"1996","journal-title":"Stat Med"},{"key":"R24-3-20210131","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(06)68580-2","article-title":". Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.","volume":"367","author":"Ferradini","year":"2006","journal-title":"Lancet"},{"key":"R25-3-20210131","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/QAD.0b013e328045c4d7","article-title":". Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.","volume":"21","author":"Laurent","year":"2007","journal-title":"AIDS"},{"key":"R27-3-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","article-title":". Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.","volume":"367","author":"Braitstein","year":"2006","journal-title":"Lancet"},{"key":"R28-3-20210131","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":". Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review.","volume":"10","author":"Barth","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"R29-3-20210131","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","article-title":". Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.","volume":"353","author":"Ledergerber","year":"1999","journal-title":"Lancet"},{"key":"R30-3-20210131","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archinte.160.8.1123","article-title":". Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.","volume":"160","author":"Paredes","year":"2000","journal-title":"Arch Intern Med"},{"key":"R31-3-20210131","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":". Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R32-3-20210131","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/00002030-200308150-00003","article-title":". Virological rebound after suppression on highly active antiretroviral therapy.","volume":"17","author":"Mocroft","year":"2003","journal-title":"AIDS"},{"key":"R33-3-20210131","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1086\/432763","article-title":". Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom.","volume":"192","author":"Pillay","year":"2005","journal-title":"J Infect Dis"},{"key":"R34-3-20210131","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/427192","article-title":". Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.","volume":"191","author":"Harrigan","year":"2005","journal-title":"J Infect Dis"},{"key":"R35-3-20210131","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.aids.0000131310.52526.c7","article-title":". The prevalence of antiretroviral drug resistance in the United States.","volume":"18","author":"Richman","year":"2004","journal-title":"AIDS"},{"key":"R36-3-20210131","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/QAI.0b013e31819c16f4","article-title":". Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.","volume":"51","author":"Mercier","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R38-3-20210131","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1086\/430387","article-title":"Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavirritonavir or nelfinavir.","volume":"191","author":"King","year":"2005","journal-title":"J Infect Dis"},{"key":"R39-3-20210131","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/QAD.0b013e32832ba8ec","article-title":". Antiretroviral medication adherence and the development of class-specific antiretroviral resistance.","volume":"23","author":"Gardner","year":"2009","journal-title":"AIDS"},{"key":"R41-3-20210131","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","article-title":". Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.","volume":"26","author":"Ajose","year":"2012","journal-title":"AIDS"},{"key":"R42-3-20210131","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1086\/428852","article-title":". HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.","volume":"191","author":"Harrigan","year":"2005","journal-title":"J Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-201304010-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T03:51:57Z","timestamp":1714621917000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201304010-00003"}},"subtitle":["Results From the ANRS 1215 Cohort"],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31827a2a7a","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,1]]}}}